A statistical issue about a phase III multi-regional trial for the survival data under accelerated failure time model with unrecognized heterogeneity

DOI10.1080/03610926.2013.786787MaRDI QIDQ3462389zbMATH OpenOpenAlexFDO

Authors Feng-shou Ko

Publication date 5 January 2016

Published in Communications in Statistics: Theory and Methods (Search for Journal in Brave)

Full work available at URL https://doi.org/10.1080/03610926.2013.786787

zbMATH Keywords

heterogeneitymulti-regional studyregional sample size

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Recommendations

• An approach to determine sample size and to allocate sample size for a specific region in a multiregional trial for survival (time-to-event) data under accelerated failure time model
• Sample Size Determination and Rational Partition for A Multi- Regional Trial for Survival (Time-To-Event) Data with Unrecognized Heterogeneity that Interacts with Treatment
• A design for survival studies: A multi-regional trial with unrecognized heterogeneity
• Comparisons of allocating sample size rationally into individual regions under heterogeneous effect size in a multiregional trial by a fixed effect model and a random effect model
• Analysis of Accelerated Hazards Models

Cites work

• Misspecified proportional hazard models
• Properties of Proportional-Hazards Score Tests under Misspecified Regression Models
• The use of frailty hazard models for unrecognized heterogeneity that interacts with treatment: considerations of efficiency and power

Cited in

(6)

• Comparisons of allocating sample size rationally into individual regions under heterogeneous effect size in a multiregional trial by a fixed effect model and a random effect model
• A design for survival studies: A multi-regional trial with unrecognized heterogeneity
• An approach to determine sample size and to allocate sample size for a specific region in a multiregional trial for survival (time-to-event) data under accelerated failure time model
• The issue about sample size for survival analysis considering the interaction of unrecognized heterogeneity and treatment
• An issue about the efficacy for the time-to-event outcome based on accelerated failure time model with interaction of unrecognized heterogeneity and main effect
• Comparisons of a multi-regional trial for four or five regions by fixed effect model and random effect model about allocating sample size rationally into individual regions for a multi-regional trial

This page was built for publication: A statistical issue about a phase III multi-regional trial for the survival data under accelerated failure time model with unrecognized heterogeneity

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3462389)